Respiratory Diseases/Disorders

Phase 3 Results Announced for Combination COPD Therapy

Forest Laboratories and Almirall announced positive top line results from AUGMENT COPD, the second six-month Phase 3 clinical trial evaluating the safety and efficacy of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered in the Pressair inhaler.

Positive Results for Combination COPD Therapy

Almirall and Forest Laboratories announced positive results from a six-month pivotal Phase 3 clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide, a long-acting muscarinic antagonist and formoterol fumarate, a long-acting beta-agonist delivered by Almirall’s inhaler Pressair.